Skip to main content

Advertisement

SpringerLink
Log in

Interferon-α/β upregulate IL-15 expression in vitro and in vivo: analysis in human hepatocellular carcinoma cell lines and in chronic hepatitis C patients during interferon-α/β treatment

  • Original Article
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

Type I interferon (IFN) possesses antiviral and antitumor activities and also having an immune regulatory effect, activating cellular immune response and upregulating several cytokines. Recent study has shown that type I IFN upregurates the dendritic cell production of IL-15 capable of activating natural killer cells and CD8+ memory T lymphocytes. However, it is still unknown if type I IFN induces IL-15 production in non-immune cells and if type I IFN affects IL-15 production in vivo. The present study investigated the effect of type I IFNs on IL-15 expression in hepatocellular carcinoma (HCC) cell lines in vitro and in patients with chronic hepatitis C in vivo. When three HCC cell lines, Huh7, HepG2, and JHH4 were cultured in vitro, IFN upregulation of IL-15 expression was observed at both the mRNA and protein levels. In experiments using Huh7 cells, upregulation of IL-15 expression occurred within 24 h of the start of IFN stimulation, and both IFN-α and -β dose-dependently increased IL-15 production in the range from 100 U/ml to 10,000 U/ml of concentration. IFN-β showed stronger activity in IL-15 production induction in vitro than IFN-α. For in vivo examination, sera were obtained from 21 chronic hepatitis C patients treated with IFN and 29 healthy individuals, and the serum IL-15 level was quantified by ELISA. The serum IL-15 level of chronic hepatitis C patients before IFN treatment was similar to that of the healthy controls and significantly increased only during the IFN administration period. These results confirm that IFN-α/β induce IL-15 production and also suggest that IL-15 may be associated with type I IFN-induced immune response.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Alter HJ (1995) To C or not to C: these are the questions. Blood 85:1681–1695

    PubMed  CAS  Google Scholar 

  2. Tong MJ, el-Farra NS, Reikes AR et al (1995) Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 332:1463–1466

    Article  PubMed  CAS  Google Scholar 

  3. Tanaka K, Ikematsu H, Hirohata T et al (1996) Hepatitis C virus infection and risk of hepatocellular carcinoma among Japanese: possible role of type 1b (II) infection. J Natl Cancer Inst 88:742–746

    Article  PubMed  CAS  Google Scholar 

  4. Tagger A, Donato F, Ribero ML et al (1999) Case-control study on hepatitis C virus (HCV) as a risk factor for hepatocellular carcinoma: the role of HCV genotypes and the synergism with hepatitis B virus and alcohol. Brescia HCC Study. Int J Cancer 81:695–699

    Article  PubMed  CAS  Google Scholar 

  5. Hayashi J, Furusyo N, Ariyama I et al (2000) A relationship between the evolution of hepatitis C virus variants, liver damage, and hepatocellular carcinoma in patients with hepatitis C viremia. J Infect Dis 181:1523–1527

    Article  PubMed  CAS  Google Scholar 

  6. Davis GL, Balart LA, Schiff ER et al (1989) Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 321:1501–1506

    Article  PubMed  CAS  Google Scholar 

  7. Di Bisceglie AM, Martin P, Kassianides C et al (1989) Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 321:1506–1510

    Article  PubMed  CAS  Google Scholar 

  8. Kakumu S, Arao M, Yoshioka K et al (1990) Recombinant human alpha-interferon therapy for chronic non-A, non-B hepatitis: second report. Am J Gastroenterol 85:655–659

    PubMed  CAS  Google Scholar 

  9. Hayashi J, Ohmiya M, Kishihara Y et al (1994) A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C. Am J Gastroenterol 89:2151–2156

    PubMed  CAS  Google Scholar 

  10. Hayashi J, Kishihara Y, Ueno K et al (1998) Age-related response to interferon alfa treatment in women vs men with chronic hepatitis C virus infection. Arch Intern Med 158:177–181

    Article  PubMed  CAS  Google Scholar 

  11. Furusyo N, Hayashi J, Ohmiya M et al (1999) Differences between interferon-alpha and -beta treatment for patients with chronic hepatitis C virus infection. Dig Dis Sci 44:608–617

    Article  PubMed  CAS  Google Scholar 

  12. Nishiguchi S, Kuroki T, Nakatani S et al (1995) Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346:1051–1055

    Article  PubMed  CAS  Google Scholar 

  13. Yoshida H, Shiratori Y, Moriyama M et al (1999) Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT study group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med 131:174–181

    PubMed  CAS  Google Scholar 

  14. Kashiwagi K, Furusyo N, Kubo N et al (2003) A prospective comparison of the effect of interferon-alpha and interferon-beta treatment in patients with chronic hepatitis C on the incidence of hepatocellular carcinoma development. J Infect Chemother 9:333–340

    Article  PubMed  CAS  Google Scholar 

  15. Stark GR, Kerr IM, Williams BR et al (1998) How cells respond to interferons. Annu Rev Biochem 67:227–264

    Article  PubMed  CAS  Google Scholar 

  16. Meurs EF, Galabru J, Barber GN et al (1993) Tumor suppressor function of the interferon-induced double-stranded RNA-activated protein kinase. Proc Natl Acad Sci USA 90:232–236

    Article  PubMed  CAS  Google Scholar 

  17. Yano H, Iemura A, Haramaki M et al (1999) Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines. Hepatology 29:1708–1717

    Article  PubMed  CAS  Google Scholar 

  18. Murphy D, Detjen KM, Welzel M et al (2001) Interferon-alpha delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin-dependent kinases. Hepatology 33:346–356

    Article  PubMed  CAS  Google Scholar 

  19. Takaoka A, Hayakawa S, Yanai H et al (2003) Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 424:516–523

    Article  PubMed  CAS  Google Scholar 

  20. von Hoegen P (1995) Synergistic role of type I interferons in the induction of protective cytotoxic T lymphocytes. Immunol Lett 47:157–162

    Article  PubMed  Google Scholar 

  21. Hiroishi K, Tuting T, Lotze MT (2000) IFN-alpha-expressing tumor cells enhance generation and promote survival of tumor-specific CTLs. J Immunol 164:567–572

    PubMed  CAS  Google Scholar 

  22. Biron CA, Nguyen KB, Pien GC et al (1999) Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 17:189–220

    Article  PubMed  CAS  Google Scholar 

  23. Ohzato H, Monden M, Yoshizaki K et al (1993) Systemic production of interleukin-6 following acute inflammation. Biochem Biophys Res Commun 197:1556–1562

    Article  PubMed  CAS  Google Scholar 

  24. Kawakami Y, Hayashi J, Ueno K et al (1997) Elevation of serum soluble interleukin-2 receptor levels in patients with hepatitis C virus infection. Fukuoka Igaku Zasshi 88:274–282

    PubMed  CAS  Google Scholar 

  25. Mattei F, Schiavoni G, Belardelli F et al (2001) IL-15 is expressed by dendritic cells in response to type I IFN, double-stranded RNA, or lipopolysaccharide and promotes dendritic cell activation. J Immunol 167:1179–1187

    PubMed  CAS  Google Scholar 

  26. Grabstein KH, Eisenman J, Shanebeck K et al (1994) Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 264:965–968

    Article  PubMed  CAS  Google Scholar 

  27. Carson WE, Giri JG, Lindemann MJ et al (1994) Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med 180:1395–1403

    Article  PubMed  CAS  Google Scholar 

  28. Kennedy MK, Glaccum M, Brown SN et al (2000) Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 191:771–780

    Article  PubMed  CAS  Google Scholar 

  29. Sharif-Askari E, Fawaz LM, Tran P et al (2001) Interleukin 15-mediated induction of cytotoxic effector cells capable of eliminating Epstein-Barr virus-transformed/immortalized lymphocytes in culture. J Natl Cancer Inst 93:1724–1732

    Article  PubMed  CAS  Google Scholar 

  30. Lodolce JP, Boone DL, Chai S et al (1998) IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 9:669–676

    Article  PubMed  CAS  Google Scholar 

  31. Zhang X, Sun S, Hwang I et al (1998) Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity 8:591–599

    Article  PubMed  CAS  Google Scholar 

  32. Liu K, Catalfamo M, Li Y et al (2002) IL-15 mimics T cell receptor crosslinking in the induction of cellular proliferation, gene expression, and cytotoxicity in CD8+ memory T cells. Proc Natl Acad Sci USA 99:6192–6197

    Article  PubMed  CAS  Google Scholar 

  33. Hayashi J, Yoshimura E, Kishihara Y et al (1996) Hepatitis C virus RNA levels determined by branched DNA probe assay correlated with levels assessed using competitive PCR. Am J Gastroenterol 91:314–318

    PubMed  CAS  Google Scholar 

  34. Strehlau J, Pavlakis M, Lipman M et al (1997) Quantitative detection of immune activation transcripts as a diagnostic tool in kidney transplantation. Proc Natl Acad Sci USA 94:695–700

    Article  PubMed  CAS  Google Scholar 

  35. Smith XG, Bolton EM, Ruchatz H et al (2000) Selective blockade of IL-15 by soluble IL-15 receptor alpha-chain enhances cardiac allograft survival. J Immunol 165:3444–3450

    PubMed  CAS  Google Scholar 

  36. Conti F, Frappier J, Dharancy S et al (2003) Interleukin-15 production during liver allograft rejection in humans. Transplantation 76:210–216

    Article  PubMed  CAS  Google Scholar 

  37. McInnes IB, al-Mughales J, Field M et al (1996) The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis. Nat Med 2:175–182

    Article  PubMed  CAS  Google Scholar 

  38. McInnes IB, Leung BP, Sturrock RD et al (1997) Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis. Nat Med 3:189–195

    Article  PubMed  CAS  Google Scholar 

  39. Lu J, Giuntoli RL, 2nd, Omiya R et al (2002) Interleukin 15 promotes antigen-independent in vitro expansion and long-term survival of antitumor cytotoxic T lymphocytes. Clin Cancer Res 8:3877–3884

    PubMed  CAS  Google Scholar 

  40. Lewko WM, Smith TL, Bowman DJ et al (1995) Interleukin-15 and the growth of tumor derived activated T-cells. Cancer Biother 10:13–20

    PubMed  CAS  Google Scholar 

  41. Yajima T, Nishimura H, Ishimitsu R et al (2002) Overexpression of IL-15 in vivo increases antigen-driven memory CD8+ T cells following a microbe exposure. J Immunol 168:1198–1203

    PubMed  CAS  Google Scholar 

  42. Klebanoff CA, Finkelstein SE, Surman DR et al (2004) IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci USA 101:1969–1974

    Article  PubMed  CAS  Google Scholar 

  43. Fehniger TA, Cooper MA, Caligiuri MA (2002) Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine Growth Factor Rev 13:169–183

    Article  PubMed  CAS  Google Scholar 

  44. Brentjens RJ, Latouche JB, Santos E et al (2003) Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 9:279–286

    Article  PubMed  CAS  Google Scholar 

  45. Wang T, Niu G, Kortylewski M et al (2004) Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10:48–54

    Article  PubMed  CAS  Google Scholar 

  46. Radaeva S, Jaruga B, Hong F et al (2002) Interferon-alpha activates multiple STAT signals and down-regulates c-Met in primary human hepatocytes. Gastroenterology 122:1020–1034

    Article  PubMed  CAS  Google Scholar 

  47. Azimi N, Shiramizu KM, Tagaya Y et al (2000) Viral activation of interleukin-15 (IL-15): characterization of a virus-inducible element in the IL-15 promoter region. J Virol 74:7338–7348

    Article  PubMed  CAS  Google Scholar 

  48. Jinushi M, Takehara T, Tatsumi T et al (2003) Autocrine/paracrine IL-15 that is required for type I IFN-mediated dendritic cell expression of MHC class I-related chain A and B is impaired in hepatitis C virus infection. J Immunol 171:5423–5429

    PubMed  CAS  Google Scholar 

  49. Damdinsuren B, Nagano H, Sakon M et al (2003) Interferon-beta is more potent than interferon-alpha in inhibition of human hepatocellular carcinoma cell growth when used alone and in combination with anticancer drugs. Ann Surg Oncol 10:1184–1190

    Article  PubMed  Google Scholar 

  50. Domanski P, Nadeau OW, Platanias LC et al (1998) Differential use of the betaL subunit of the type I interferon (IFN) receptor determines signaling specificity for IFNalpha2 and IFNbeta. J Biol Chem 273:3144–3147

    Article  PubMed  CAS  Google Scholar 

  51. Rani MR, Foster GR, Leung S et al (1996) Characterization of beta-R1, a gene that is selectively induced by interferon beta (IFN-beta) compared with IFN-alpha. J Biol Chem 271:22878–22884

    Article  PubMed  CAS  Google Scholar 

  52. Rani MR, Gauzzi C, Pellegrini S et al (1999) Induction of beta-R1/I-TAC by interferon-beta requires catalytically active TYK2. J Biol Chem 274:1891–1897

    Article  PubMed  CAS  Google Scholar 

  53. Yamaji K, Hayashi J, Kawakami Y et al (1998) Hepatitis C viral RNA status at two weeks of therapy predicts the eventual response. J Clin Gastroenterol 26:193–199

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of General Medicine, Kyushu University Hospital, 3-3-1, Maidashi Higashiku, Fukuoka, 812-8582, Japan

    Kouzaburo Yamaji, Shigeki Nabeshima, Masayuki Murata, Yong Chong, Norihiro Furusyo, Hideyuki Ikematsu & Jun Hayashi

Authors
  1. Kouzaburo Yamaji
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shigeki Nabeshima
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masayuki Murata
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yong Chong
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Norihiro Furusyo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hideyuki Ikematsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jun Hayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kouzaburo Yamaji.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yamaji, K., Nabeshima, S., Murata, M. et al. Interferon-α/β upregulate IL-15 expression in vitro and in vivo: analysis in human hepatocellular carcinoma cell lines and in chronic hepatitis C patients during interferon-α/β treatment. Cancer Immunol Immunother 55, 394–403 (2006). https://doi.org/10.1007/s00262-005-0005-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-005-0005-x

Keywords

Search

Navigation